drugset / Trial / NCT06379113

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

NCT06379113

Phase 2/3 Recruiting 29 enrolled Xiaojun Chen
NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.

Timeline

Start
2022-07-13
Primary completion
2026-03-30
Completion
2027-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral